Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth

Curcumin has been reported to exhibit anti-tumorigenic activity; however, since its precise actions remain unclear, its effects are considered to be deceptive. In the present study, we confirmed the anti-tumorigenic effects of curcumin on CML-derived leukemic cells in a xenograft model and in vitro culture system. In vitro pull-down and mass analyses revealed a series of enzymes (carbonyl reductase, glutathione-S-transferase, glyoxalase, etc.) that function in a reactive oxygen species (ROS) metabolic pathway as curcumin-binding targets, the expression of which was up-regulated in human leukemia. Curcumin increased ROS levels over the threshold in leukemic cells, and the antioxidant, glutathione (GSH) and overexpression of curcumin-binding enzymes partially mitigated the up-regulation of ROS and growth inhibition caused by curcumin. These results show that curcumin specifically inhibits tumor growth by increasing ROS levels over the threshold through the miscellaneous inhibition of ROS metabolic enzymes. Curcumin has potential in therapy to regulate ROS levels in tumor cells, thereby controlling tumor growth.

[1]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[2]  K. Davies.  The Broad Spectrum of Responses to Oxidants in Proliferating Cells: A New Paradigm for Oxidative Stress , 1999, IUBMB Life - A Journal of the International Union of Biochemistry and Molecular Biology.

[3]  L. Laino,et al.  Biological and therapeutic activities, and anticancer properties of curcumin. , 2015, Experimental and therapeutic medicine.

[4]  T. Finkel,et al.  Cellular mechanisms and physiological consequences of redox-dependent signalling , 2014, Nature Reviews Molecular Cell Biology.

[5]  E. Ellis.  Reactive carbonyls and oxidative stress: potential for therapeutic intervention. , 2007, Pharmacology & therapeutics.

[6]  N. Chandel,et al.  Physiological roles of mitochondrial reactive oxygen species. , 2012, Molecular cell.

[7]  R. Ahmad,et al.  Studies on biomarkers for oxidative stress in patients with chronic myeloid leukemia. , 2009, Hematology/oncology and stem cell therapy.

[8]  M. Mouret-Reynier,et al.  Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer , 2010, Cancer biology & therapy.

[9]  S. Inoue,et al.  Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. , 2015, Cancer cell.

[10]  N. Vermeulen,et al.  Inhibition of human glutathione S-transferases by curcumin and analogues , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  K. Rathinasamy,et al.  Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. , 2008, Biochimica et biophysica acta.

[12]  Jianhua Xu,et al.  Down-regulation of p210bcr/abl by curcumin involves disrupting molecular chaperone functions of Hsp90 , 2006, Acta Pharmacologica Sinica.

[13]  Jayme L. Dahlin,et al.  The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.

[14]  T. Das,et al.  Anti cancer effects of curcumin: cycle of life and death , 2008, Cell Division.

[15]  E. Maser,et al.  Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1. , 2015, Chemico-biological interactions.

[16]  B. Liu,et al.  ROS and p53: a versatile partnership. , 2008, Free radical biology & medicine.

[17]  J. Lotem,et al.  Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[20]  K. Huse,et al.  Curcumin Inhibits Glyoxalase 1—A Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity , 2008, PloS one.

[21]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[22]  Sigrid A. Langhans,et al.  Anaphase-promoting complex/cyclosome protein Cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis , 2012, BMC Cancer.

[23]  D. Bonnet,et al.  Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation , 2006, Leukemia.

[24]  Susan O'Brien,et al.  Very long‐term follow‐up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy , 2012, Cancer.

[25]  T. Mak,et al.  Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.

[26]  M. Santoro,et al.  ROS homeostasis and metabolism: a dangerous liason in cancer cells , 2016, Cell Death and Disease.

[27]  Jun Kato,et al.  Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Peng Huang,et al.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.

[29]  M. Bissell.  Early Cytogenetic and Molecular Response During First-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase: Long-Term Implications , 2013 .

[30]  M. Baker.  Deceptive curcumin offers cautionary tale for chemists , 2017, Nature.

[31]  J. Kato,et al.  Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3 , 2005, The EMBO journal.

[32]  J. Overbaugh.  Gender bias: track revisions and appeals , 2017, Nature.

[33]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[34]  G. Georgiou,et al.  Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth , 2016, Nature Medicine.

[35]  Jorge Cortes,et al.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.